Sustainability & Climate

Private equity firm TruArc Partners acquires Matrix Adhesives, signaling a strategic push to consolidate the booming North American adhesives market.

HistoSonics begins a landmark trial for a non-invasive BPH therapy that uses focused ultrasound to mechanically destroy tissue without incisions or heat.

A new drug not only reduces osteoarthritis pain significantly but may also be the first to modify the disease itself, a landmark study in The Lancet reveals.

As Precigen leaders prepare for a key investor chat, all eyes are on the explosive launch of PAPZIMEOS and the company's ambitious path to profitability.

Food-tech firm Beyond Oil is rolling out its oil-purifying tech in a top U.S. supermarket, promising healthier fried food and significant cost savings.

Defying retail trends, luxury menswear brand Enzo Custom bets big on physical showrooms and a new digital platform to make high-end tailoring accessible.

Avory & Co. enters the crowded ETF market with AVRY, an actively managed fund shunning trends for a concentrated portfolio of high-quality stocks.

A new company, PrimeTech, is launching with AI-driven design and a decentralized factory model to tackle labor shortages and build homes faster.

LIB Therapeutics' new monthly, room-temperature stable cholesterol drug shows strong long-term data, challenging rivals with a focus on patient ease-of-use.

As $50B in federal funds flow to rural health, Ovatient's new platform aims to create a sustainable virtual care model that will outlast the grants.

Japanese pharma giant Meiji Seika Pharma backs Centivax's quest for a universal flu vaccine, a move that could revolutionize global pandemic preparedness.

After promising results in a key patient subgroup, the PREVAiLS study will test if pridopidine can slow the relentless progression of ALS.

Doble Engineering's new handheld Spark P2 detector promises to revolutionize power grid maintenance with its portability and user-friendly advanced diagnostics.

Neumora reveals promising data for Alzheimer's and schizophrenia drugs, but a delay in its obesity program highlights the high-stakes world of biotech.

As millions grapple with Cannabis Use Disorder, a small biotech's lead drug enters Phase 3 trials, promising the first-ever FDA-approved treatment.

Forget thread count. The future of bedding is about microclimate regulation, certified safety, and sustainable materials. See how PHF is leading the charge.

As Q1 results loom, the gold giant is expected to post strong figures amid high prices. Investors are watching its cash pile, costs, and hybrid AGM.

Analyses reveal the EPA allows pesticides with high cancer risks on the market without warning labels, raising major public health and legal questions.

Newly-listed Blossom Gold hires a top IR exec, pursues a US dual listing, and launches a massive drilling program to fast-track its Nevada gold project.

Japanese innovator Tenchijin joins a top French accelerator, bringing its satellite-AI tech to tackle Europe's aging and leaky water infrastructure.